Home/Filings/8-K/0001193125-26-006996
8-K//Current report

STANDARD BIOTOOLS INC. 8-K

Accession 0001193125-26-006996

$LABCIK 0001162194operating

Filed

Jan 7, 7:00 PM ET

Accepted

Jan 8, 7:10 AM ET

Size

294.6 KB

Accession

0001193125-26-006996

Research Summary

AI-generated summary of this filing

Updated

Standard BioTools Inc. Reports Preliminary Q4 and FY2025 Results

What Happened

  • On January 8, 2026, Standard BioTools Inc. (LAB) issued a press release (attached as Exhibit 99.1) disclosing certain preliminary financial results for the three months and fiscal year ended December 31, 2025.
  • The reported figures are preliminary and unaudited, based on current expectations, and may be adjusted as a result of completion of annual audit procedures and final closing processes.

Key Details

  • Date of report and press release: January 8, 2026.
  • Period covered: three months and fiscal year ended December 31, 2025.
  • Status of results: preliminary, unaudited, subject to completion of financial closing and audit procedures.
  • Filing status: information furnished (Exhibit 99.1), not “filed” under Section 18 and not automatically incorporated by reference into other registration statements.

Why It Matters

  • This is an early update on LAB’s earnings and financial condition for Q4/FY2025; preliminary results can move investor expectations for revenue, profitability and guidance.
  • Because the numbers are unaudited and may change, investors should treat this as provisional information and await the final audited results (typically in the Form 10-K or a subsequent 8-K) before making decisions.
  • Look for the company’s subsequent filings or investor release for final audited figures and management commentary to assess trends in revenue, margins, and cash flow.